|
Abstract Objective: To explore the infection of human parvovirus B19 of pregnant women during different pregnancy stages, and to study the influence of human parvovirus B19 infection on adverse pregnancy outcomes. Methods: Human parvovirus B19 IgM of 2240 pregnant women were detected by enzyme-linked immunosorbent assay from January 2016 to December 2017. Results: The infection rate of human parvovirus B19 was 2.2%. There were no significant difference in the infection rate among pregnant women with different age, parity and number of fetuses (P>0.05). The infection rate of women in equal to or less than 12 gestational weeks was 3.5%, which was significant higher than that (1.6%) of women in 13-28 gestational weeks and that (1.8%) of women over 28 gestational weeks (P<0.05). The incidences of stillbirth, fetal malformation, fetal edema and abortion of infected pregnant women were 10.7%, 21.4%, 7.1%, and 7.14%, respectively, which were significant higher than those (0.3%, 0.2%, 0.1%, 0.6%, respectively) of women without human parvovirus B19 infection (P<0.05). There was no significant difference in adverse pregnancy outcomes of women in different gestational weeks (P>0.05). Conclusion: There is a certain proportion of human parvovirus B19 infection in pregnant women, which is associated with the adverse pregnancy outcomes, so it is necessary to strengthen the monitoring of parvovirus B19 infection in pregnant women.
|
|
|
|
|
|
